that weaken the fibrous cap making lesions vulnerable 
order has led to an exploration of new avenues in the pathogenesis of this disease. In this sense, the levels of Atherosclerosis is currently described as an inflammaseveral inflammatory molecules in circulating blood are tory disease [1] , given that the main components of chronic increased more frequently in subjects at risk of develinflammation such as cell recruitment, sclerosis, cell prooping an acute coronary event [12] [13] [14] [15] [16] . This reflects a liferation and neovascularization are present in this prorelationship between the events that are taking place in cess. Moreover, recruitment of inflammatory cells is inthe blood and into the vessel wall. This is not surprising volved in plaque rupture and subsequent thrombosis.
since, as explained, inflammatory cells are circulating in Atherosclerotic lesions are formed by a lipid-rich nucleus the blood before entering the atherosclerotic lesion. In covered by a fibrous cap. This cap confers the lesions fact, using a rabbit model of atherosclerosis, we demonresistance to rupture, and consists of collagen and other strated a significant correlation between the inflammaextracellular matrix proteins, synthetized by vascular tory activity of circulating monocytes and that of the smooth muscle cells (VSMC) [2] [3] . Inflammatory cells, cells present in the atherosclerotic plaques [17] . Tomainly macrophages, release metalloproteinases (MMP) gether, these data suggest that the grade of activity of inflammatory cells is determined before they enter the arterial wall. Another advance derived from the inflam-anti-inflammatory actions [13, [18] [19] [20] . Moreover, our data indicate that even a small amount of red wine, which 
Recruitment of mononuclear cells ANTI-INFLAMMATORY EFFECTS OF STATINS
After adhesion, monocytes enter the arterial wall in Since the demonstration that hydroxy-methyl-glutaryl a process driven by chemoattractant molecules. HMGcoenzyme A (HMG-CoA) reductase inhibitors (statins) CoA reductase inhibitors have been shown to extenreduce mortality and the incidence of coronary events sively interfere with this step. In a rabbit model of athero-[22], great effort has been made to elucidate the underlysclerosis we demonstrated that atorvastatin decreases ing mechanisms of these effects. Angiographic studies rethe expression of chemoattractant molecules MCP-1 and vealed that the reduction in lesion progression achieved interleukin-8 (IL-8) [20, 38] . As a consequence, there by these drugs was too mild to fully explain them [23] .
was a reduction in macrophage infiltration and MMP-3 Also, the clinical benefits appear after too short an interexpression. The mechanism of the reduction of MCP-1 val of treatment time to see any significant effect on plaque and IL-8 expression seemed to be due to a decrease in progression [24] . Extensive research carried out mainly in the activation of nuclear factor-B (NF-B; Fig. 1 ). This the last decade suggests that, instead of an improvement redox-sensitive transcription factor is involved in the transin endothelial function [25] , the clinical benefit of these mission of various signals from the cytoplasm to the nudrugs could be related to a reduction in blood thrombocleus of numerous cell types [39] . It is found in the cytosol genicity [26] and to anti-inflammatory properties. Moreas a trimer consisting of p50 and p65 subunits bound to over, it has been shown that these actions in part could its inhibitor IB. The release of IB from the trimer be independent of the lipid-lowering effects of statins.
results in the migration of the p50/p65 heterodimer to the This review focuses on the anti-inflammatory and immunucleus and subsequent DNA binding [40] . This process nomodulatory actions of statins (Table 1) .
activates genes involved in the immune, inflammatory or acute phase response, such as adhesion molecules, cheEndothelial dysfunction and adhesion moattractant cytokines like MCP-1 and IL-8, proinflamOne of the early stages in atherogenesis is the adhesion matory enzymes such as cyclooxygenase-2 (COX-2), and of monocytes to the endothelium, which acquires an procoagulant proteins as tissue factor (TF) and plasminactivated phenotype due to various stimuli. This activaogen activator inhibitor-1 (PAI-1) [41, 42] . Data strongly tion is believed to be related to a decrease in nitric oxide suggest that NF-B could be involved in the pathogenesis (NO) availability, which may be secondary to different of atherosclerosis sis, but is absent in the healthy vessel [48] . In addition, -9 and tissue factor in the same model, and decreases macrophage proliferation and the proteolytic activity COX-2 has been demonstrated to colocalize with prostaglandin E 2 (PGE 2 ) synthase, with macrophages and due to MMP-9 in human macrophages in vitro [51] . The same group demonstrated that pravastatin and fluva-MMP-9 in human carotid atherosclerosis [49] . Of interest, COX-2 expression was more intense in the lesions statin reduced MMP-3 and MMP-9 expression in the absence of modifications of the macrophage infiltrate, of patients who had suffered an ipsilateral stroke [49] .
These atherosclerotic plaque may induce an immune response. They studied patients with symptomatic carotid stenosis One of these possible antigens, heat-shock protein 70 who were scheduled for a carotid endarterectomy [54] .
has been demonstrated to be present around sites of Three months before the operation, the patients were necrosis and lipid accumulation, colocalizing with macrorandomized to pravastatin versus no lipid-lowering therphages, in human and rabbit atheroma [72] . Other proapy and, at surgery, endarterectomy specimens were colposed antigens, such as low-density lipoprotein (LDL) lected and analyzed. Patients receiving pravastatin had and non-LDL oxidative epitopes, are also more freless macrophage and T cell infiltration, reduced MMP-2 quently present in atherosclerotic than in normal human expression as well as a higher immunoreactivity for tissue arteries [73] . In fact, T cells derived from human atheroinhibitor of MMP-1. Probably as a result of the lower sclerosis respond to oxLDL by proliferation and cytokine collagenolytic activity, the collagen content was higher in secretion [74] . It also has been speculated that infectious patients on pravastatin therapy, suggesting a stabilizing agents could stimulate immunity in this disorder [75, 76] . effect of atherosclerotic lesions.
The presence of activated T lymphocytes in the peripheral blood and coronary plaques of patients with acute Inflammatory serum markers and statins coronary syndromes supports the hypothesis of an imDifferent markers of inflammation have been studied mune response in the pathogenesis of coronary atheroto analyze the effect of statins on inflammatory states. In sclerosis [7, [76] [77] [78] . According to this hypothesis, there particular, high-sensitivity C-reactive protein (hs-CRP)
is an increase of CD4ϩ and CD3ϩ/DRϩ T cells and reflects low-grade systemic inflammation [55] . Human of IL-2 and IgM in patients with unstable angina [75] . studies have demonstrated that statins are able to reduce Furthermore, in this condition, monocytes present nu-CRP serum levels in hyperlipidemic patients [14, 56-59], clear translocation of STAT-1 complexes and up-regulaincluding those who are on hemodialysis [60] . The importion of CD64 and IP-10 genes, which are known to be tance of this effect is related to the demonstration that inducible by interferon-␥ (IFN-␥) [79] . This points to a the increment of CRP levels has a predictive value of possible monocytic activation via IFN-␥ produced by the possibility of an acute coronary event [13-16, 61]. stimulated T lymphocytes. In accordance with this hyAccordingly, these drugs are especially effective in repothesis, it has been observed that monocytes need incuducing the incidence of coronary events in the population bation and contact with lymphocytes to express procoagwith high levels of CRP [14, 62] . ulant activity [80] . Different adhesion molecules such as VCAM-1, ICAM-1 Different effects of statins on lymphoid cell function and E-selectin also have been proposed as markers of have been shown. For example, suppression of proliferacardiovascular risk [63] [64] [65] . Statin therapy decreases tion or natural killer cell activity by compactin [81] , lova-E-selectin levels and the effects on other adhesion molestatin [82] and simvastatin [83] has been reported in cule levels have been discordant [37, 66] .
in vitro experiments. Lovastatin, by binding to LFA-1, Other inflammatory molecules are affected by statins.
exerts an immunomodulatory effect, because this integSerum MMP-9 levels, which have been found to increase rin does not only play a role in leukocyte adhesion, but during acute coronary syndromes [67] , are decreased by does also work as a T cell co-stimulator [36]. Kwak et pravastatin in clinically healthy men, reflecting the reducal demonstrated that different statins inhibit the exprestion of nonsymptomatic chronic arterial inflammation sion of major histocompatibility class II (MHC II) anti- [68] . Hypercholesterolemic individuals treated with pragens by primary human macrophages and endothelial vastatin and simvastatin show a reduction in the levels of cells in response to IFN-␥ [84] . This effect resulted from the proinflammatory cytokines tumor necrosis factor-␣ the reduced activation of the inducible promoter IV on (TNF-␣) [69, 70] and IL-1␤ [70] . Finally, the activity of the transactivator CIITA [85] and was limited to cells the transcription factor NF-B in circulating leukocytes that express MHC II only in response to IFN-␥ stimulais enhanced in patients with unstable angina and in healthy tion [84] . In contrast, professional antigen-presenting volunteers after a fat-enriched meal [21, 71] . Treatment cells constitutively expressing MHC II, such as B lymwith simvastatin reduces this activity in mononuclear cirphocytes and dendritic cells, were not inhibited, and neither was MHC I expression. culating cells in the rabbit model of atherosclerosis [17] .
Major histocompatibility class II antigen is required MECHANISMS OF ANTI-INFLAMMATORY EFFECTS OF STATINS for antigen presentation and T-cell activation through the T cell receptor. This T-cell receptor may trigger prolif-
Actions related to lipid lowering eration of other T cells, their differentiation into two difStatins were developed as lipid-lowering drugs. HMGferent effector cell populations (T helper 1 and 2 cells;
CoA reductase inhibition leads to a decrease in intracelTh1 and Th2) and cytokine release. In this sense, Th1 lular cholesterol synthesis. To compensate for the intracells secrete proinflammatory cytokines such as IFN-␥ cellular diminution in cholesterol levels, some cells, mainly and TNF-␣. In contrast, Th2 cells produce anti-inflamhepatocytes, expose external receptors that promote upmatory cytokines interleukin-4 (IL-4), IL-10, IL-13 and take and clearance of cholesterol from the blood. Given transforming growth factor-␤ (TGF-␤). It has been sugthe relationship between hyperlipidemia and atherosclegested that the ability of statins to down-regulate the rosis, it seems wise to consider that their hypolipidemic expression of MHC II may lead to decreased Th1 activaeffect is responsible for a part of their biological actions, tion in vivo and inhibition of the pro-inflammatory cytoincluding the anti-inflammatory effects. kines release. Accordingly, statins reduce T cell proliferIn human studies, it has been observed that hyperchoation and IL-2 release [84] . However, these drugs may lesterolemia up-regulates the pro-inflammatory receptor induce opposite effects via a similar impact on Th2 prolif-CD40 and its ligand CD40L [95] . This system is expressed eration and effector function or shift toward a Th1 imin the cells of the atherosclerotic lesions where it medimune response [86] .
ates the production of cytokines, MMPs and tissue factor Clinical research has been carried out to examine the [96] . Moreover, levels of soluble CD40L are increased immunomodulatory effect of statins, and the results have in acute coronary syndromes [97, 98] and predict their incidence in healthy women [99] . In animal models, hybeen discordant. Muldom et al did not find any effect perlipidemia also enhances NF-B activation, the expresof six months of lovastatin on the number and function sion of adhesion and chemoattractant molecules, and faof circulating immune cells [87] [88] . Moreover, although it had increases NF-B activation and MMP-9 expression in no effect on the incidence of mild and moderate episodes culture human monocyte-derived macrophages [101] . Also, of cardiac rejection, pravastatin decreased the incidence CD40L expression and IFN-␥ production are enhanced of rejection with hemodynamic impairment and reduced by lysophosphatidylcholine in human CD4ϩ T cells [102] . mortality [88] . In a similar population, Wenke et al Probably the best data confirming that a part of the showed that simvastatin significantly increased survival anti-inflammatory effects of statins are related to lipid and reduced the incidence of coronary artery disease lowering arise from animal experimentation. Aikawa and intimal thickness at four years of follow-up, although et al demonstrated that reducing lipid levels only by it did not affect the incidence of cardiac rejection [89] .
dietary modification, in the rabbit model of atheroscleroData on kidney-transplanted patients are, for the mosis, decreases the expression of CD40 and CD40L coloment, less promising. Although a small study with 48 calizing with a reduction of tissue factor immunoreactivpatients showed a decrease in acute rejection [90], three ity [103] . Also, a diminution of macrophage infiltrate, larger randomized trials involving a total of 570 patients MMP-1 expression and proteolytic activity was observed failed to confirm these data [91] [92] [93] . However, in these in the same model [104] . Together these data underline studies the patients were followed for only three months, the fact that lipid lowering is one of mechanisms by a short period when compared with the one to four years which statins decrease inflammation in atherosclerosis. reported in the cardiac transplant studies [88, 89] . Thus, it would be interesting to know the effects of prolonged Lipid-independent mechanisms statin administration and a longer follow-up period in A large body of data has accumulated in the last years this population. The ongoing ALERT trial may shed suggesting that some effects of statins, for example, their some light on this issue. In this study, 2100 patients with actions on endothelial dysfunction and the anti-inflammafunctioning renal allografts and mild-to-moderate hypertory effects, could be independent of their lipid-lowering cholesterolemia are being randomized to fluvastatin or ability. This was supported by clinical studies such as the placebo and will be followed up to six years. Although WOSCOPS study, where evidence showed that patients the primary objective of this trial is the incidence of major on pravastatin had fewer coronary events than those on adverse cardiac events, it will also provide information placebo who had similar LDL levels [105] . Moreover, in the same study, plasma lipids at baseline did not influence on renal function and all causes of mortality [94] . the relative risk reduction achieved by pravastatin. In tachment of an isoprenoid residue to these proteins is necessary for their anchorage to the cell membranes and addition, the fall in LDL found in the pravastatin group did not correlate with the risk reduction of coronary full functionality. Statins inhibit Ras and Rho isoprenylation leading to the accumulation of their inactive forms heart disease.
Evidence pointing to a direct anti-inflammatory action in the cytoplasm [112] . These proteins are implicated in different functions in the cells such as gene expression, of HMG-CoA reductase inhibitors comes from both clinical and experimental studies. The reduction of CRP organization of the actin cytoskeleton, membrane trafficking, programmed cell death, proliferation and transserum levels achieved by different statins is not related to the decrease in lipid levels [14, [57] [58] [59] [60] .
formation [113, 114] . Inhibition of Rho and its downstream target, Rho kinase, is a possible mechanism Research in animal models of atherosclerosis strongly supports the idea of a direct anti-inflammatory effect of mediating some of the pleiotropic effects of HMG-CoA reductase inhibitors on the vascular wall, since changes statins. Williams et al showed a decrease in macrophage infiltration in atherosclerotic monkeys after treatment in Rho can affect intracellular transport, membrane trafficking, mRNA stability, and gene transcription [115] . with pravastatin and diet manipulation to avoid changes in serum lipid levels [106] . More recently, simvastatin Accordingly, we have seen, for example, that atorvastatin directly reduces the expression of MCP-1 and IL-8 has been found to reduce inflammation in a model of carrageenan-induced footpad edema in mice [107] . Simas well as NF-B activation induced by angiotensin II (Ang II) and TNF-␣ in cultured monocytes and VSMC vastatin also has been found to reduce leukocyte rolling and adherence in rats [108] and apolipoprotein E-defi- [116] . These effects have been related to the inhibition of non-sterol compounds of the mevalonate pathway, cient mice [109] , leukocyte transmigration in rats [108] and the aorta cholesterol content in apolipoprotein such as FPP and GGPP, which restored the inhibition of NF-B activity induced by atorvastatin. Moreover, E-deficient mice [107] in the absence of lipid change. In a recent work from our group, atherosclerotic rabbits Manumicyn A, an isoprenylation inhibitor, abolishes were randomized to simvastatin treatment and a hyper-NF-B activity induced by Ang II and TNF-␣ [116] . lipidemic diet versus a normolipidemic diet. Given that Other transcription factors also seem to be regulated the hyperlipidemic diet counterbalanced the effect of by statins. Treatment with different statins can modulate simvastatin, the reduction of lipid levels in this group proinflammatory cytokines expression such as IL-1␤, was less pronounced. However, NF-B activity in mono-IL-6, and COX-2 by up-regulating the peroxisome prolifnuclear cells and atherosclerotic lesions was reduced erator activated receptor-␣ in endothelial cells [117] . Acmore markedly in the simvastatin group [17] . Similar tivator protein-1 (AP-1) activation is decreased by statin results were obtained when macrophage infiltration and treatment in renal epithelial tubular cells [118] . In addithe expression of IL-8 and MMP-3 were analyzed. The tion, atorvastin and simvastatin increase the activation observation that simvastatin had a greater anti-inflamof the octamer transcription factor Oct-1 in mononuclear matory action than diet modification in spite of less lipid cells, which represses the transcription of proinflammalowering, suggests that a part of these effects may be tory genes such as IL-8, CD11c/CD18, VCAM1 and due to mechanisms independent of lipid modification.
PECAM-1 [119] . Despite the information obtained in vivo, the most comFinally, it must be noted that HMG-CoA reductase prehensive information about the mechanism of the direct inhibition is not the only possible mechanism through actions of statins results from in vitro experiments. In which statins exert their effects. The above-mentioned these studies, the effect of HMG-CoA reductase inhibiinhibitory action of lovastatin on LFA-1 is unrelated to tion on the cell types that form the atherosclerotic lesions this pathway [36] . This opens the possibility of develwas tested (Fig. 2) . Given that the cells were isolated oping new statins with selectively potentiated immunofrom the whole organism, the possibility of a decrease suppressive effects. in extracellular lipids by the action of these drugs on the liver disappeared, and it was possible to observe solely OTHER EFFECTS OF STATINS ON THE their action on the studied cells. It was found that the VASCULAR WALL RELATED WITH lipid-independent effects of these agents are related to
SMALL G PROTEINS the inhibition of other isoprenoid intermediates of the cho-
The accumulation of VSMC in the neointima is anlesterol biosynthetic pathway, such as farnesylpyrophosother feature of atherosclerosis and a consequence of phate (FPP) and geranylgeranylpyrophosphate (GGPP) their migration from the media and their proliferation [110] . FPP and GGPP are used for the post-translational within the lesion [1] . Different studies have demonstrated modification of several important cell proteins including that treatment with statins inhibits proliferation of VSMC nuclear lamins, Heme-a, the ␥ subunit of heterotrimeric by arresting the cell cycle transition between the G 1 to S G proteins, and small G proteins such as Ras and Raslike proteins (Rac, Rab and Rho; Fig. 2) [111] . The atphase. The inhibition of VSMC proliferation was corre- lated with increases in the level of cyclin-dependent kiincreased fibrinolytic capacity, which is related to the inhibition of PAI-1 expression from VSMC and endothelial nase inhibitor p27
Kip1 and is related with the inhibition of RhoA isoprenylation [120] . Antiproliferative effects cells [126] . Ang II plays crucial roles in the pathogenesis of cardiovascular diseases, and statins down-regulate of statins in animal models without significant changes in serum cholesterol concentrations also have been reAng II type 1 receptor in VSMC, an effect related again with the inhibition of RhoA isoprenylation (Fig. 3) [127] . ported [121, 122] . In addition, serum of patients treated with statins decreases proliferation of VSMC in vitro [123] .
Statins and postangioplasty restenosis The accumulation of VSMC in the early step of atherosclerosis is the result of the migration from the media, One of the most important challenges in the treatment of coronary artery disease is postangioplasty restenosis. proliferation and eventual death, including programmed cell death. In this sense, we have demonstrated that lipoThis process is not identical to the evolution of spontaneous atherosclerosis, and is due to both intima thickening philic statins induced apoptosis of VSMC in culture and this effect is related with the interference of protein with VSMC proliferation, and arterial wall remodeling. In the last years, the use of stents has reduced the inciisoprenylation [124] . These experiments used higher concentrations than those used in clinical practice, but it is dence of restenosis by controlling arterial remodeling [128, 129] , and stents are now implanted electively after possible that relatively low, but sustained plasma levels of statins could exert a similar effect to that seen in vitro angioplasty in most cases. Despite the antiproliferative effect of statins, several with higher concentrations. In this regard, Buemi et al have demonstrated that there is an increment of apoptostudies have evidenced that these drugs fail to prevent restenosis after balloon angioplasty [130] [131] [132] [133] . However, sis in cultured VSMC following the addition of the serum of fluvastatin-treated patients [125] .
in a subset of patients treated with stent, statins seem to be beneficial. Walter et al have evidenced recently that Furthermore, different reports have demonstrated another pleiotropic effect of statins related to the inhibition these drugs reduce the incidence of post-stent restenosis specifically in those patients whose serum C reactive of small G proteins isoprenylation. Statins may alter the local fibrinolytic balance within the vessel wall toward protein levels are above 0.6 mg/dL [134] . These data point to a role for inflammation in restenosis. Accordaccount that atherosclerosis in animals is induced by stronger stimuli than those present in human disease, ingly, it has been shown that patients who develop unstasuch as vessel injury and/or experimental diets that raise ble angina following directional coronary atherectomy lipid levels far greater than that seen in humans. Hence, have more macrophages and T lymphocytes in the aththe use of high doses of statins in these studies seems to erosclerotic lesions than those who have only stable anbe proportional to the aggressive disease induced. The gina or stay asymptomatic [135] . Thus, although most same problem arises when interpreting in vitro studies. promising therapies, such as local delivery of antiprolif-
The concentrations used to demonstrate the biological erative drugs, are now introduced to control post-stent effects of statins in cell culture, especially with regard restenosis [136] , statins may provide a positive effect in to inhibition of Rho gerenylgeranylation, appear to be this situation due to their anti-inflammatory effects. much higher than those prescribed clinically. However, it is possible that concentrations of statins needed to LIMITATIONS TO THE INTERPRETATION OF affect activated cells are lower than those needed to THE LITERATURE affect normal cells. In addition, one may assume that in Combining clinical with experimental data, as in this vivo, relatively low, but sustained blood levels of statins review, provides a comprehensive way to explain the could exert a similar effect to that seen in vitro with benefit and mechanisms of action of any drug. However, higher concentrations and short incubation times. the value and limitations of every source of knowledge Another common question when analyzing drug acmust be clearly pointed out. One of the most common tions is whether there is a "class effect" and all the memproblems in nonclinical drug experimentation is the dose bers of a family share the same properties, or if there are employed. Most animal studies reported here employed differences among their actions. Although differences in proportionally higher doses of statins than those used other effects of statins have been noted, such as those on platelet aggregation, coagulation and fibrinolysis [137] , in clinical practice. Nevertheless, it must be taken into terol lowering (Fig. 3) . In particular, in vitro and in vivo 
